ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,061.40
0.37%
US Tech 100
20,860.40
0.13%
다우존스 지수
44,930.47
0.49%
Bitcoin
104,867.03
1.09%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Lyell Immunopharma Inc (LYEL)

  7. Lyell Immunopharma Inc (LYEL) 뉴스

Lyell Immunopharma Inc

Lyell Immunopharma Inc (LYEL)

NASDAQ
0.5799
0.0001
( 0.02% )
업데이트: 03:10:17
15분 지연

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

LYEL 뉴스

공식 뉴스 전용

Form 8-K - Current report
Edgar (US Regulatory)
25 1월 2025
LYEL (0.02%)

Form 8-K/A - Current report: [Amend]
Edgar (US Regulatory)
10 1월 2025
LYEL (0.02%)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Edgar (US Regulatory)
09 12월 2024
LYEL (0.02%)

Form EFFECT - Notice of Effectiveness
Edgar (US Regulatory)
06 12월 2024
LYEL (0.02%)

Form S-3 - Registration statement under Securities Act of 1933
Edgar (US Regulatory)
30 11월 2024
LYEL (0.02%)

Form 8-K - Current report
Edgar (US Regulatory)
27 11월 2024
LYEL (0.02%)

Form 8-K - Current report
Edgar (US Regulatory)
08 11월 2024
LYEL (0.02%)

Form 8-K - Current report
Edgar (US Regulatory)
01 11월 2024
LYEL (0.02%)

Form 8-K - Current report
Edgar (US Regulatory)
25 10월 2024
LYEL (0.02%)

LYEL Discussion

게시물 보기
glenn1919 glenn1919 4 주 전
LYEL.................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 3 월 전
lyel..............................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 3 월 전
LYEL................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
jondoeuk jondoeuk 3 월 전
As a reminder, the ORR was ~12.5% for LYL797. BMY's JCAR024 had an ORR of 5-6%, but was discontinued, while a Fred Hutch construct showed no responses.
👍️0
jondoeuk jondoeuk 3 월 전
An update https://www.globenewswire.com/news-release/2024/10/24/2969054/0/en/Lyell-Immunopharma-to-Acquire-ImmPACT-Bio-and-Prioritizes-its-Pipeline-to-Focus-on-Next-Generation-CAR-T-cell-Therapies.html

The webcast https://lyell-company-update-2024.open-exchange.net/registration

Slides https://ir.lyell.com/static-files/40d6bd34-9ad0-49dd-b816-4bda3bd53eb0
👍️0
glenn1919 glenn1919 3 월 전
LYEL..........................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
jondoeuk jondoeuk 4 월 전
Preclinical data (Stim-R tech) https://www.nature.com/articles/s41598-024-72392-1
👍️0
glenn1919 glenn1919 5 월 전
LYEL..................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
jondoeuk jondoeuk 8 월 전
(OT) Dr Restifo is Co-founder and Chief Scientist at Marble Therapeutics. From this: ''At Marble Therapeutics, he is working to figure out how to rewind the epigenetic clock on these cells, using any means possible. The company started out with a focus on skin rejuvenation, adds CEO Denitsa Milanova, but expanded to also work on adoptive cell therapy to prove their platform works.'' https://web.archive.org/web/20231218233715/https://www.nature.com/articles/d41573-023-00206-6

They have a license for TIL plus a neoantigen vaccine https://www.federalregister.gov/documents/2024/02/07/2024-02491/prospective-grant-of-an-exclusive-patent-license-vaccine-augmented-adoptive-cell-therapy-for-the

Preclinical data on the vaccine https://jitc.bmj.com/content/11/Suppl_1/A418
🎯 1 👍️ 1
glenn1919 glenn1919 10 월 전
LYEL.....................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 10 월 전
LYEL active in the Gaucho session

👍️0
jondoeuk jondoeuk 10 월 전
Tempting but I will remain on the sidelines.
👍️0
Monksdream Monksdream 10 월 전
LYEL under $3
👍️0
glenn1919 glenn1919 10 월 전
LYEL..................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
jondoeuk jondoeuk 1 년 전
They could be working on this https://ash.confex.com/ash/2023/webprogram/Paper182417.html
👍️0
jondoeuk jondoeuk 1 년 전
Upcoming https://www.globenewswire.com/news-release/2023/09/27/2750444/0/en/Lyell-Immunopharma-Announces-the-Acceptance-of-Six-Abstracts-for-Presentation-at-2023-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting.html
👍️0
Monksdream Monksdream 1 년 전
LYEL new 52 week low
👍️0
jondoeuk jondoeuk 2 년 전
LYL119 https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=13739
👍️0
jondoeuk jondoeuk 2 년 전
Preclinical data from another group (LYL119 will be NR4A3-deficient) https://www.biorxiv.org/content/10.1101/2023.04.21.537841v1.full
👍️0
glenn1919 glenn1919 2 년 전
LYEL..........................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
jondoeuk jondoeuk 2 년 전
The FDA has cleared an IND for LYL845. The PhI trial will initially enroll patients with relapsed and/or refractory metastatic or locally advanced melanoma and subsequently expand into NSCLC and CRC. Initial data presentation is expected in 2024.
👍️0
jondoeuk jondoeuk 2 년 전
SITC titles

NR4A3 gene editing and c-Jun overexpression synergize to limit exhaustion and enhance functional activity of ROR1 CAR T cells in vitro and in vivo

Engineering potent CAR T-cell therapies by controlling T-cell activation signaling parameters using the Stim-R™ technology, a programmable synthetic cell-signaling platform

The Epi-R™ technology produces a polyclonal TIL product (LYL845) with diverse tumor-reactive clones that have stem-like qualities and anti-tumor function

The Epi-R™ technology produces a polyclonal TIL product (LYL845) with a greater expansion success rate across hot and cold tumors, improved product phenotype, and maintenance of TCR diversity

Increased potency and functional persistence in vitro of a next-generation NY-ESO-1-specific TCR therapy incorporating Gen-R™ genetic reprogramming technology
👍️0
NY1972 NY1972 3 년 전
recent technical advances using culture conditions with IL-7/IL-15 and
the addition of IL-21 may enhance the enrichment for TSCM cells
in the final CART product (74–76), which can be further increased
with the addition of drugs blocking T-cell differentiation, such as
glycogen synthase-3 inhibitors (77). Nevertheless, robust clinical grade protocols for generating TSCM-enriched CART products
have not been developed so far. Recently, a few CART19 clinical
trials for DLBCL have been conducted in which CART products
were manufactured from CD62L+ isolated T cells to generate
cellular products enriched for TCM cells (21, 78); however, due to
prolonged culture conditions, enrichment for TSCM and TCM
subsets in the infused product could not be demonstrated

https://www.frontiersin.org/articles/10.3389/fimmu.2022.904497/full
👍️0
jondoeuk jondoeuk 3 년 전
The AEs from the LD chemo*. I expect more data (dose expansion is ongoing) from them at ASH. As for NVS, a pivotal trial is planned and DL2 (12.5M) is the recommended dose.

* Some very early clinical data testing an anti-GD2 CAR-T with constitutive signaling from an engineered IL-7 receptor
👍️0
NY1972 NY1972 3 년 전
Thanks for the link.
Most commonly reported grade 3/4 AEs were neutrophil count decrease (6/9, 67%), anemia (5/9, 56%), thrombocytopenia (2/9,22%), platelet count decrease (2/9, 22%) and no infection was reported. Complete response rate(CRR) was 78%

Compared to T-Charge
http://www.koreabiomed.com/news/articleView.html?idxno=12767

👍️0
jondoeuk jondoeuk 3 년 전
For Epi-R, they use media with high concentrations of potassium (as well as multiple cytokines). As for that, T-Charge or BE, I think a product with mostly ''stem-like'' cells and additional edits will be needed. But it doesn't have to be the latter, as shRNA can be used. Here are some clinical data on an anti-CD19 CAR-T with knock-down of both PD-1 and TIGIT https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7522
👍️0
NY1972 NY1972 3 년 전
Which will perform better ? BE with 7,8 edits on many genes, Epi secret sauce
or T-Charge which seems to add a CAR only to starting material in order to retain CD4/CD8 ratio.
YTB323 CAR-T cell products generated via this novel expansionless manufacturing process retained the immunophenotype of the input leukapheresis materia
👍️0
jondoeuk jondoeuk 3 년 전
That depends. Typically, the more the cells expand during manufacturing, the more they differentiate. In the case of ALLO, it seems most are effector memory (manufacturing time is ~19 days and there are a number of steps involved). LYEL refer to this as the expansion/quality paradox. With Epi-R, they have shown they can expand TCR-T cells up to 18 billion by day ten. In addition, these cells are over 94% viable and maintain their ''stem-like'' qualities.
👍️0
NY1972 NY1972 3 년 전
Do you need Epigenetic Reprogramming if pts can be treated with healthy, young donor T cells?
👍️0
jondoeuk jondoeuk 3 년 전
ISSCR poster https://ir.lyell.com/static-files/971404cb-28eb-46fc-839f-b20735899373
👍️0
jondoeuk jondoeuk 3 년 전
Posters https://ir.lyell.com/static-files/d3a3d05c-1b39-4092-bf82-a486933bc268

https://ir.lyell.com/static-files/6014be8d-4e9d-499b-a496-513d2962f3e4
👍️0
jondoeuk jondoeuk 3 년 전
1115: Epigenetic Reprogramming (Epi-R™) Yields T-Cell Receptor Products with Improved Stemness, Metabolic Fitness, and Functional Activity in the Presence of Persistent Antigen Exposure https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=2014

661: Preclinical Development of LYL797, a ROR1-Targeted CAR T-Cell Therapy Enhanced with Genetic and Epigenetic Reprogramming for Solid Tumors https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=1597
👍️0
jondoeuk jondoeuk 3 년 전
GSK has updated the master protocol for their next generation constructs to include a third arm with GSK4427296 https://clinicaltrials.gov/ct2/show/NCT04526509

This uses Epi-R.
👍️0
jondoeuk jondoeuk 3 년 전
AACR poster https://ir.lyell.com/static-files/ad2cd8dc-b41b-4536-a854-c4d1246422e6
👍️0
jondoeuk jondoeuk 3 년 전
The PhI (n=54) of LYL797 has now been listed. The dose-escalation phase (TNBC only) will investigate four dose levels to determine the recommended RP2D. The dose expansion will enroll both TNBC and NSCLC.
👍️0
jondoeuk jondoeuk 3 년 전
A new review https://www.sciencedirect.com/science/article/pii/S0952791521001278
👍️0
jondoeuk jondoeuk 3 년 전
Morgan Stanley webcast https://morganstanley.webcasts.com/viewer/event.jsp?ei=1488969&tp_key=3cedc4a917
👍️0
jondoeuk jondoeuk 4 년 전
New deck https://ir.lyell.com/static-files/96379999-4d8e-466b-a5d5-44f5f6f88583
👍️0

최근 히스토리

NASDAQ
LYEL
Lyell Immunopharma
LSE
16HX
Lloyds Bk. 48
ASX
UBNDA
Urbanise com
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지